NCT07038447View on ClinicalTrials.gov

A Study of KITE-363 in Participants With Refractory Autoimmune Diseases

PHASE1Enrolling by invitationINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

July 2, 2025

Primary Completion Date

July 31, 2029

Study Completion Date

July 31, 2029

Conditions
Systemic Lupus ErythematosusLupus NephritisSystemic SclerosisIdiopathic Inflammatory Myopathy
Interventions
BIOLOGICAL

KITE-363

A single infusion of CAR-transduced autologous T cells administered intravenously

DRUG

Fludarabine

Administered intravenously

DRUG

Cyclophosphamide

Administered intravenously

Trial Locations (1)

2139

Concord Repatriation General Hospital, Syndey

All Listed Sponsors
lead

Kite, A Gilead Company

INDUSTRY